SynthesisPloS one2021
Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Herpes zoster incidence and burden in older Chinese: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.The European respiratory journal · 2024Pooled it
- The association between varicella zoster virus and dementia: a systematic review and meta-analysis of observational studies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- TFOS lifestyle: Impact of societal challenges on the ocular surface.The ocular surface · 2023Pooled it
- Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2022Pooled it
- Clinical and epidemiological characteristics of herpes zoster at a tertiary care center compared to population-based data: a ten-year retrospective cohort study.BMC infectious diseases · 2026Article
- Burden of herpes zoster and postherpetic neuralgia in Jinan, China: incidence, recurrence, and direct medical costs, 2018-2023, a population-based retrospective cohort study.BMC infectious diseases · 2026Article
- Real-World Vaccination Data Analysis for Three Vaccines Among Individuals Aged 60 and Older in Shanghai, China.Vaccines · 2026Article
- Herpes zoster burden in a private healthcare setting of Argentina.Frontiers in public health · 2026Article
- Clinical epidemiology of herpes zoster and postherpetic neuralgia in Barcelona (Spain). A single-center study.Frontiers in public health · 2026Article
- Incidence of herpes zoster in Afro-descendant populations: a systematic literature review.BMJ public health · 2026Article
- Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study.Human vaccines & immunotherapeutics · 2025Article
- Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China.Human vaccines & immunotherapeutics · 2025Article
- Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine Adverse Event Reporting System database.Human vaccines & immunotherapeutics · 2025Article
- Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil.Human vaccines & immunotherapeutics · 2025Article
- Clinical and economic burden of herpes zoster in Mexico: A retrospective medical chart analysis in a private healthcare setting.Human vaccines & immunotherapeutics · 2025Article
- Genomic evidence of varicella-zoster virus among Mpox-suspected cases in Ethiopia during the 2022 Mpox multi-country outbreak.Scientific reports · 2025Article
- Demographical and Clinical Characteristics, Risk Factors, and Prognosis of Adult Patients with Herpes Zoster in Türkiye: A Retrospective, Multi-Center Study (VARICOMP-Adult Study).Infectious disease reports · 2025Article
- Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy.Vaccines · 2025Review
- Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology and burden of Herpes Zoster (HZ) are largely unknown, and there are no recent reviews summarizing the available evidence from the Latin America and Caribbean (LAC) region. We conducted a systematic review and meta-analysis to characterize the epidemiology and burden of HZ in LAC. Bibliographic databases and grey literature sources were consulted to find studies published (January 2000 -February 2020) with epidemiological endpoints: cumulative incidence and incidence density (HZ cases per 100,000 person-years), prevalence, case-fatality rates, HZ mortality, hospitalization rates, and rates of each HZ complication. Twenty-six studies were included with most studies coming from Brazil. No studies reported the incidence of HZ in the general population. In population at higher risk, the cumulative incidence ranged from 318-3,423 cases of HZ per 100,000 persons per year of follow-up. The incidence density was 6.4-36.5 cases per 1,000 person-years. Age was identified as a major risk factor towards HZ incidence which increase significantly in people >50 years of age. Hospitalization rates ranged from 3%-35.7%. The in-hospital HZ mortality rate ranged from 0%-36%. Overall, HZ mortality rates were found to be higher in females across all age groups and countries. The incidence of HZ complications (such as post-herpetic neuralgia, ophthalmic herpes zoster, and Ramsay Hunt syndrome) was higher in the immunosuppressed compared to the immunocompetent population. Acyclovir was the most frequently used therapy. Epidemiological data from Ministry of Health databases (Argentina, Brazil, Colombia, Chile y Mexico) and Institute for Health Metrics and Evaluation's Global Burden of Disease project reported stable rates of hospitalizations and deaths over the last 10 years. High-risk groups for HZ impose a considerable burden in LAC. They could benefit from directed healthcare initiatives, including adult immunization, to prevent HZ occurrence and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.